Patents by Inventor Géraldine GROUARD-VOGEL

Géraldine GROUARD-VOGEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS
    Publication number: 20230364232
    Abstract: An immunogenic product including at least one immunoglobulin or fragment thereof conjugated with a carrier protein, wherein the at least one immunoglobulin is IgE and preferably wherein the IgE fragment includes the IgE C?3 domain, and wherein the carrier protein is preferably CRM197. Also the use of this immunogenic product for treating inflammatory disorders, and in particular allergic disorders.
    Type: Application
    Filed: September 17, 2021
    Publication date: November 16, 2023
    Applicants: NEOVACS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR
    Inventors: Laurent REBER, Pierre BRUHNS, Eva CONDE GARCIA, Marija BACKOVIC, Vincent SERRA, Géraldine GROUARD-VOGEL, Romain BERTRAND
  • IMMUNOGENIC PRODUCT COMPRISING IL-4 AND/OR IL-13 FOR TREATING DISORDERS ASSOCIATED WITH ABERRANT IL-4 AND/OR IL 13 EXPRESSION OR ACTIVITY
    Publication number: 20210205427
    Abstract: An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM197. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.
    Type: Application
    Filed: May 29, 2019
    Publication date: July 8, 2021
    Applicants: NEOVACS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR
    Inventors: Géraldine GROUARD-VOGEL, Eva CONDE GARCÌA, Romain BERTRAND, Noémie CAILLOT, Laurent REBER, Pierre BRUHNS, Vincent SERRA
  • METHOD FOR TREATING IFNALPHA RELATED CONDITIONS
    Publication number: 20180207288
    Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.
    Type: Application
    Filed: March 26, 2018
    Publication date: July 26, 2018
    Inventors: Geraldine GROUARD-VOGEL, Olivier DHELLIN, Bernard FANGET, Pierre VANDEPAPELIERE, Camille ROUCAIROL
  • Method for treating IFNalpha related conditions
    Patent number: 9993565
    Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: June 12, 2018
    Assignee: NEOVACS
    Inventors: Geraldine Grouard-Vogel, Olivier Dhellin, Bernard Fanget, Pierre Vandepapeliere, Camille Roucairol
  • METHOD FOR TREATING IFNALPHA RELATED CONDITIONS
    Publication number: 20140023617
    Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.
    Type: Application
    Filed: April 4, 2012
    Publication date: January 23, 2014
    Applicant: NEOVACS
    Inventors: Geraldine Grouard-Vogel, Olivier Dhellin, Bernard Fanget, Pierre Vandepapeliere, Camille Roucairol
  • STRONGLY INACTIVATED AND STILL HIGHLY IMMUNOGENIC VACCINE AND PROCESS OF MANUFACTURING THEREOF
    Publication number: 20130259892
    Abstract: An immunogenic product includes TNF? coupled with KLH, wherein the TNF? is strongly inactivated, which means that the product shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A. An emulsion and a vaccine including the product and methods for preparing the immunogenic product are also described.
    Type: Application
    Filed: December 8, 2011
    Publication date: October 3, 2013
    Inventors: Geraldine Grouard-Vogel, Olivier Dhellin, Bernard Fancet, Pierre Vandepapeliere
  • STRONGLY INACTIVATED AND STILL HIGHLY IMMUNOGENIC VACCINE AND PROCESS OF MANUFACTURING THEREOF
    Publication number: 20120148526
    Abstract: An immunogenic product includes TNF? coupled with KLH, wherein the TNF? is strongly inactivated, which means that the product shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A. An emulsion and a vaccine including the immunogenic product and methods for preparing the immunogenic product are also described.
    Type: Application
    Filed: December 8, 2010
    Publication date: June 14, 2012
    Applicant: NEOVACS
    Inventors: Géraldine GROUARD-VOGEL, Olivier DHELLIN, Bernard FANGET, Pierre VANDEPAPELIÈRE